despit
earli
discoveri
interferon
ifn
ifn
lambda
identifi
recent
year
classifi
new
group
type
iii
ifn
human
distinct
protein
call
identifi
also
name
respect
member
new
ifn
famili
found
interact
uniqu
receptor
distinct
type
type
ii
ifn
receptor
receptor
type
iii
ifn
compos
uniqu
chain
also
call
chain
share
receptor
complex
although
type
iii
ifn
bind
specif
receptor
downstream
signal
similar
induc
type
ifn
type
type
iii
ifn
stimul
common
signal
pathway
consist
activ
kinas
lead
activ
ifnstimul
gene
factor
transcript
complex
compos
interferon
regulatori
factor
figur
although
three
gene
encod
highli
homolog
distinct
human
protein
search
mous
genom
reveal
exist
two
gene
repres
mous
gene
orthologu
locat
chromosom
encod
intact
protein
mous
gene
orthologu
pseudogen
contain
variat
addit
stop
codon
first
exon
code
activ
protein
clone
mous
receptor
orthologu
found
quit
similar
human
counterpart
experi
show
similar
human
counterpart
signal
receptor
complex
activ
capabl
induc
antivir
protect
mhc
class
antigen
express
sever
cell
type
result
show
murin
type
iii
ifn
engag
uniqu
receptor
complex
compos
subunit
induc
signal
biolog
activ
similar
type
ifn
interestingli
contrast
type
type
ii
ifn
type
iii
ifn
demonstr
less
speci
specif
although
type
type
iii
induc
similar
cell
signal
intens
cell
signal
measur
activ
appear
significantli
lower
type
iii
ifn
comparison
type
ifn
restrict
cell
type
respond
type
iii
ifn
figur
interestingli
find
strict
correl
intens
cell
signal
induc
level
biolog
activ
exampl
melanoma
cell
although
induc
weak
activ
comparison
observ
robust
stimul
mhc
class
express
cell
surfac
indic
potenti
contribut
cellspecif
modul
activ
antivir
studi
perform
vitro
vivo
shown
contribut
overal
host
antivir
defens
system
demonstr
induc
antivir
activ
vsv
vesicular
stomat
viru
emcv
encephalomyocard
mani
human
cell
line
howev
use
differ
mous
model
viral
infect
ank
et
al
demonstr
effect
dna
viru
simplex
viru
rna
virus
emcv
lymphocyt
choriomening
viru
lcmv
sever
studi
demonstr
type
iii
ifn
also
inhibit
replic
hepat
c
viru
hcv
hepat
b
viru
hbv
vitro
studi
import
sinc
underlin
fact
could
use
altern
hcv
patient
resist
treatment
report
abil
inhibit
human
immunodefici
viru
type
infect
blood
monocytederiv
macrophag
express
receptor
herp
simplex
viru
type
infect
human
astrocyt
neuron
howev
case
antivir
potenc
sever
virus
seem
lower
addit
may
induc
distinct
signal
transduct
gene
regul
kinet
moreov
type
activ
plethora
innat
adapt
immun
mechan
help
elimin
tumor
viral
infect
immunoregulatori
function
includ
major
histocompat
complex
mhc
class
express
normal
tumor
cell
activ
nk
cell
dendrit
cell
dc
macrophag
result
promot
adapt
immun
respons
tumor
viral
infect
cell
role
immun
system
current
investig
sever
group
far
data
suggest
exert
immunomodulatori
effect
overlap
type
ifn
recent
demonstr
human
modul
human
plasmacytoid
dc
function
cytokin
respons
treatment
whole
peripher
blood
mononuclear
cell
pbmc
upregul
express
tnf
cytokin
product
inhibit
examin
purifi
cell
popul
also
shown
activ
monocyt
rather
lymphocyt
result
secret
panel
cytokin
suggest
may
import
activ
innat
immun
respons
particularli
site
viral
infect
also
shown
possess
immunoregulatori
function
helper
respons
markedli
inhibit
howev
moder
effect
observ
import
cytokin
respons
immunoregulatori
function
enhanc
express
cell
find
correl
data
suggest
may
immunoprotect
role
asthma
allergi
diseas
caus
exagger
respons
similar
produc
dc
respons
tolllik
receptor
tlr
stimul
found
specif
effect
dc
differenti
matur
includ
partial
matur
dc
upregul
mhc
class
ii
molecul
induct
costimulatori
molecul
differenti
monocyt
dc
acquir
respons
express
interestingli
dc
treat
promot
gener
tolerogen
dc
prolifer
regulatori
cell
treg
recent
morrow
et
al
demonstr
dna
vaccin
plasmid
encod
like
abl
enhanc
adapt
immun
howev
contrast
reduc
regulatori
tcell
popul
also
show
unlik
abl
increas
percentag
splenic
cell
vaccin
anim
complet
protect
mice
death
follow
lethal
influenza
challeng
studi
altogeth
highlight
strong
candidaci
potenti
novel
immunotherapeut
agent
addit
antivir
immunomodulatori
activ
type
ifn
demonstr
antiprolif
activ
cell
line
activ
seem
restrict
type
ifn
shown
induc
apoptosi
tumor
cell
yet
molecular
mechan
mediat
cell
death
respons
ifn
remain
fulli
explain
bind
correspond
cellular
receptor
complex
ifn
induc
quick
potent
signal
lead
express
ifnstimul
gene
isg
mani
isg
encod
protein
implic
apoptosi
unlik
inhibit
prolifer
sever
cell
line
includ
daudi
cell
blymphoblastoid
cell
line
burkitt
lymphoma
strongli
respond
type
ifn
antiprolif
assay
howev
demonstr
inhibit
prolifer
tumor
cell
line
human
gliobastoma
cell
line
cell
constitut
express
high
level
antiprolif
effect
demonstr
variou
tumor
cell
line
express
ectop
endogen
receptor
therefor
abil
induc
antiprolif
activ
cell
depend
level
express
recent
report
signal
colorect
adenocarcinoma
cell
led
caspas
activ
extern
phosphatidylserin
ps
dna
fragment
result
subsequ
apoptosi
studi
provid
evid
first
time
type
iii
ifn
alon
combin
stimuli
potenti
induc
apoptosi
moreov
anoth
recent
studi
reveal
differ
antiprolif
effect
correl
differ
durat
jakstat
signal
activ
two
ifn
prolong
isg
express
upon
treatment
use
human
keratinocyt
hacat
cell
line
express
receptor
found
induc
pronounc
growth
inhibitori
effect
also
effici
induc
antiprolif
effect
overlap
activ
apoptosi
prolong
durat
stat
activ
isg
express
could
account
enhanc
antiprolif
proapoptot
effect
observ
hacat
cell
effect
seen
upon
treatment
high
dose
interestingli
studi
shown
induc
growth
human
multiplemyeloma
cell
antagon
dexamethasoneinduc
cell
death
cell
cell
growth
multipl
myeloma
cell
mapk
depend
high
level
found
malign
bone
marrow
microenviron
impli
may
play
direct
role
multipl
myeloma
develop
use
plasmid
electrotransf
approach
sommereyn
cowork
report
differenti
respons
mice
low
respons
liver
central
nervou
system
spleen
howev
high
respons
observ
stomach
intestin
heart
kidney
lung
respons
restrict
epitheli
cell
correl
express
paradox
mice
spite
epitheli
natur
hepatocyt
liver
express
low
level
respond
poorli
howev
signific
respons
report
human
hepatocyt
suggest
exist
variat
respons
mice
human
least
liver
although
main
target
epitheli
cell
presenc
potenti
tissuespecif
factor
may
modul
respons
receptor
recent
shown
mice
contrast
hepatocyt
promin
respons
observ
intestin
epitheli
cell
comparison
respons
higher
play
critic
role
protect
intestin
epithelium
viral
infect
strongli
suggest
promin
role
organ
mucos
surfac
least
mice
addit
direct
effect
mucos
epithelium
local
immunomodul
also
promot
function
form
two
chain
protein
also
call
uniqu
tissu
distribut
highli
restrict
contrast
share
ubiquit
express
tissu
unlik
cell
type
respond
figur
contrast
epitheliallik
cell
fibroblast
endotheli
cell
complet
unrespons
although
hematopoeit
system
primari
target
respons
subpopul
exclud
mice
found
induc
activ
plasmacytoid
myeloid
dendrit
cell
result
accord
obtain
mennechet
propos
acquisit
respons
monocyt
differenti
dendrit
cell
therefor
respons
may
control
induct
express
differ
level
found
differ
tissu
highest
level
found
gastrointestin
tract
lung
brain
show
lowest
level
receptor
express
express
also
analyz
differ
cell
type
express
cell
popul
isol
human
skin
show
high
express
keratinocyt
melanocyt
howev
dermal
fibroblast
endotheli
cell
subderm
adipocyt
express
signific
amount
signific
express
detect
primari
human
hepatocyt
comparison
chondrocyt
isol
hyalin
cartilag
knee
joint
although
express
significantli
high
lymphoid
tissu
respons
weak
impli
presenc
specif
mechan
lymphoid
tissu
may
inhibit
respons
exampl
level
b
cell
threefold
detect
keratinocyt
exhibit
one
highest
respons
witt
et
al
propos
potenti
role
solubl
highli
releas
immun
cell
weak
respons
although
interact
receptor
bind
characterist
ligand
still
investig
futur
import
analyz
activ
light
bind
cell
understand
particularli
role
possess
highest
activ
compar
analysi
ligand
bind
combin
activ
induc
also
import
understand
impact
epitheli
cell
particularli
comparison
immun
cell
express
besid
sever
carcinoma
origin
epitheli
cell
respond
tumor
aris
epitheli
cell
may
becom
sensit
report
multipl
myeloma
cell
origin
bcell
plasmocyt
show
high
bind
respons
studi
bind
transform
cell
versu
normal
cell
may
help
tumor
target
establish
optimum
dose
use
vivo
treatment
also
use
drug
carrier
specif
target
drug
tumor
express
high
bind
site
avail
knockout
mice
allow
investig
role
type
iii
ifn
vivo
use
mice
mordstein
et
al
show
first
time
contribut
innat
immun
influenza
viru
later
found
play
import
role
defens
pathogen
infect
respiratori
tract
respiratori
synciti
viru
metapneumoviru
sever
acut
respiratori
syndrom
sar
coronaviru
howev
lassa
fever
viru
replic
liver
affect
lack
although
studi
clearli
demonstr
play
import
role
protect
respiratori
gastrointestin
tract
viru
infect
comparison
type
ifn
protect
provid
type
iii
ifn
remain
limit
howev
combin
type
type
iii
may
provid
better
viral
protect
respons
type
type
iii
defici
mice
abl
clear
sar
coronaviru
intestin
compar
mice
type
type
iii
remain
function
impli
may
strengthen
antivir
activ
act
first
line
defens
mucosa
first
use
clinic
start
hepat
c
phase
studi
conduct
patient
chronic
genotyp
hepat
c
viru
infect
hcv
pegyl
combin
ribavirin
rbv
belong
class
antivir
medic
call
nucleosid
analogu
use
studi
assess
efficaci
potenti
cytotox
studi
perform
part
first
part
evalu
pegyl
singl
agent
relaps
patient
treatment
second
part
concern
combin
pegyl
rbv
treatmentrelaps
patient
third
part
evalu
pegyl
combin
rbv
patient
addit
differ
dose
microgkg
pegyl
use
fiftysix
patient
enrol
patient
use
respect
part
data
show
antivir
activ
dose
pegyl
test
patient
achiev
rapid
antivir
respons
expect
due
limit
distribut
treatment
well
toler
advers
effect
minim
flulik
symptom
limit
hematolog
suppress
report
summari
author
conclud
weekli
without
daili
rbv
week
associ
clear
antivir
activ
patient
chronic
hcv
howev
studi
lack
direct
comparison
influenc
viral
patient
genotyp
well
accept
respons
natur
clearanc
hcv
infect
depend
singlenucleotid
polymorph
snp
upstream
could
use
biomark
help
determin
treatment
outcom
first
genomewid
associ
studi
gwa
hcv
infect
report
ge
et
al
evalu
treatment
outcom
group
patient
mix
ethnic
receiv
pegyl
ribavirin
associ
discov
sustain
viral
respons
svr
treatment
cluster
seven
snp
link
gene
signific
snp
demonstr
high
statist
signific
mani
studi
replic
find
demonstr
high
link
treatment
outcom
howev
mechan
explain
link
remain
determin
clear
yet
snp
associ
constitut
product
may
play
role
hcv
clearanc
success
treatment
result
also
suggest
therapeut
potenti
combin
therapi
demonstr
hepatocellular
carcinoma
hcc
mous
model
although
engag
distinct
receptor
induc
similar
cell
signal
figur
sinc
wide
use
clinic
treat
cancer
tabl
investig
potenti
antitumor
activ
use
mous
melanoma
model
chosen
cancer
model
melanoma
aggress
cancer
one
therapeut
agent
frequent
use
treatment
melanoma
signific
improv
relapsefre
overal
surviv
postop
adjuv
therapi
report
larg
random
studi
howev
benefici
effect
obtain
patient
receiv
high
dose
intraven
five
time
per
week
studi
low
dose
shown
signific
increas
overal
surviv
usual
dose
optim
antitumor
activ
higher
maxim
toler
dose
dose
dilemma
profoundli
affect
accept
treatment
clinician
patient
advers
effect
associ
high
dose
includ
myelosuppress
nervou
system
disord
effect
often
compromis
benefici
antitumor
effect
prematur
discontinu
treatment
reduct
dose
sinc
virtual
cell
bodi
respond
surpris
patient
develop
numer
side
effect
make
dissect
benefici
harm
effect
challeng
task
requir
investig
interferon
system
investig
antitumor
effect
melanoma
use
gene
therapi
approach
consist
deliveri
gene
tumor
cell
gene
transfer
tumor
cell
use
approach
test
effect
cytokin
anim
cancer
model
approach
requir
product
purif
protein
secret
constant
amount
variou
cytokin
transduc
tumor
cell
site
tumor
growth
could
elicit
effect
antitumor
respons
act
directli
tumor
microenviron
anoth
advantag
cytokin
gene
transfer
tumor
cell
versu
system
administr
potenti
induc
antitumor
effect
without
elicit
side
effect
associ
system
administr
high
dose
cytokin
investig
potenti
antitumor
role
first
evalu
respons
melanoma
cell
analyz
activ
mhc
class
antigen
express
comparison
found
induc
weak
phosphoryl
strong
stimul
mhc
class
antigen
express
indic
differ
link
intens
cell
signalingbiolog
activ
result
warrant
investig
compar
respons
use
gene
transfer
engin
cell
constitut
produc
cell
respons
secret
cell
exhibit
constitut
high
level
mhc
class
antigen
express
syngen
mice
inject
parent
cell
develop
tumor
howev
constitut
product
cell
markedli
affect
tumorigen
cell
cell
either
reject
host
grew
slower
rate
control
parent
cell
antitumor
effect
dose
depend
cell
also
inhibit
growth
parent
cell
cell
type
inject
togeth
also
use
engin
re
cell
addit
constitut
secret
complet
resist
demonstr
lack
mhc
class
antigen
express
interestingli
similar
cell
found
reduct
tumorigen
re
cell
impli
involv
host
antitumor
mechan
induc
follow
report
character
mous
system
potent
antitumor
activ
mous
melanoma
model
independ
group
confirm
role
antitumor
agent
melanoma
tumor
model
demonstr
antitumor
activ
sato
et
al
use
mous
melanoma
cell
line
transfect
cdna
cell
show
increas
activ
caspas
induct
dephosphory
rb
trigger
cell
cycl
arrest
apoptosi
event
obtain
vitro
appar
associ
growth
delay
observ
vivo
inject
transduc
delay
tumor
growth
also
observ
administr
cell
transduc
use
cell
line
repres
metastat
mous
melanoma
cell
author
show
overexpress
significantli
inhibit
lung
metastasi
anoth
studi
evalu
antitumor
activ
numasaki
et
al
first
transduc
mous
fibrosarcoma
cell
retrovir
vector
follow
inject
engin
tumor
cell
mice
author
observ
signific
antitumor
antimetastat
effect
mice
inocul
comparison
inject
parent
tumor
cell
hcc
preval
type
liver
cancer
fifth
common
solid
tumor
third
lead
caus
cancerrel
death
worldwid
also
second
lethal
cancer
fiveyear
surviv
rate
treatment
option
hcc
limit
mainli
ineffici
exist
anticanc
chemotherapeut
drug
hcc
unfortun
due
lack
biomark
screen
hcc
patient
diagnos
advanc
stage
diseas
meet
strict
select
criteria
potenti
cur
surgic
tumor
resect
orthotop
liver
transplant
olt
patient
unresect
hcc
preserv
liver
function
transarteri
chemoembol
tace
shown
prolong
surviv
howev
tace
rare
cur
progressionfre
surviv
beyond
month
frequent
patient
advanc
diseas
system
chemotherapi
limit
benefit
resist
hcc
exist
anticanc
drug
fact
patient
hcc
die
secondari
liver
failur
cirrhosi
hcc
occur
frequent
patient
cirrhosi
result
chronic
hbv
hepat
b
viru
hcv
hepat
c
viru
infect
alcohol
abus
although
link
cancer
viral
infect
fulli
understood
yet
suggest
viral
infect
interfer
signal
transduct
consequ
disrupt
normal
control
growth
cell
sinc
use
clinic
treatment
chronic
hcv
hbv
infect
sever
studi
evalu
effect
ifn
treatment
incid
hcc
previous
shown
system
administr
high
dose
longterm
nude
mice
bear
human
hcc
high
metastat
potenti
follow
cur
resect
inhibit
tumor
metastati
recurr
major
clinic
studi
also
conclud
ifn
therapi
alon
combin
ribavirin
decreas
incid
hcc
particularli
patient
sustain
virolog
respons
therefor
ifn
alon
perhap
combin
drug
use
prevent
therapi
develop
hcc
hcv
hbvinfect
patient
howev
numer
side
effect
limit
overal
toler
particularli
patient
cirrhosi
follow
part
section
describ
find
antitumor
properti
bnl
mous
model
hcc
evalu
antitumor
activ
use
gene
therapi
approach
previous
describ
express
gene
strong
constitut
promot
bnl
cell
select
stabl
cell
line
constitut
express
sinc
constitut
express
tumor
site
found
affect
tumorigen
melanoma
cell
vivo
examin
whether
similar
effect
would
display
case
bnl
hepatoma
mice
inject
bnl
vector
parent
bnl
cell
develop
tumor
week
wherea
tumor
appear
cell
significantli
delay
similar
effect
obtain
mice
inocul
cell
experi
demonstr
constitut
express
ifn
tumor
site
result
delay
tumor
growth
vivo
interestingli
found
exhibit
similar
antitumor
activ
despit
antiprolif
effect
seem
direct
effect
tumor
cell
may
major
mechan
display
antitumor
activ
act
indirectli
tumor
inhibit
angiogenesi
induc
tumor
requir
promot
growth
metastasi
mice
bear
human
tumor
clearli
demonstr
antitumor
activ
associ
inhibit
tumor
angiogenesi
bladder
carcinoma
prostat
cancer
involv
immun
system
antitumor
mechan
strongli
suggest
gresser
et
al
earli
studi
tumor
model
shown
intact
immun
system
essenti
antitumor
activ
inhibit
friend
leukemia
cell
flc
mice
shown
depend
activ
host
cell
nk
cell
macrophag
host
humor
cellular
immun
mechan
involv
continu
suppress
friend
erythroleukemia
metastas
treatment
mice
addit
effect
adapt
immunotherapi
observ
tcell
lymphoma
model
inject
tumorsensit
spleen
cell
use
antibodi
differ
immun
cell
popul
shown
lymphocyt
lymphocyt
major
effector
antitumor
activ
induc
although
signal
quit
similarli
figur
mechan
underli
antitumor
activ
may
qualit
differ
previous
describ
initi
investig
whether
type
iii
ifn
also
possess
antitumor
activ
util
gene
therapi
approach
melanoma
model
sinc
secret
affect
prolifer
rate
melanoma
cell
vitro
studi
melanoma
model
suggest
act
host
mechan
elicit
antitumor
activ
howev
observ
signific
longlast
immun
impli
may
lack
effect
adapt
immun
mice
reject
tumor
hand
notic
reduct
tumor
vascular
presenc
suggest
potenti
role
tumor
microenviron
sinc
found
keratinocyt
highli
sensit
known
interact
melanocyt
cell
melanoma
origin
suggest
deliveri
tumor
microenviron
may
affect
function
keratinocyt
well
stroma
cell
therebi
promot
inhibit
tumor
growth
nk
cell
major
effector
innat
immun
could
also
recruit
tumor
microenviron
help
destroy
tumor
cell
two
group
report
nk
cell
play
role
antitumor
mechan
sato
et
al
describ
involv
nk
cell
melanoma
colon
cancer
antitumor
respons
shown
transient
transduct
cell
mous
cdna
enhanc
mhc
class
fa
express
suppress
cell
prolifer
induc
increas
activ
increas
level
dephosphoryl
rb
vitro
meant
abl
induc
cell
cycl
arrest
apoptot
cell
death
vitro
addit
demonstr
overexpress
inhibit
local
pulmonari
metastat
tumor
format
vivo
deplet
nk
cell
inject
antiasialo
antibodi
tumor
cell
inject
reveal
nk
cell
import
tumor
growth
inhibit
vivo
suggest
activ
innat
immun
respons
numasaki
et
al
also
implic
nk
cell
polymorphonuclear
neutrophil
cell
antitumor
activ
induc
murin
fibrosarcoma
mous
model
inocul
cell
mice
enhanc
product
cytotox
tcell
activ
spleen
antitumor
activ
partial
depend
addit
increas
total
number
splenic
nk
cell
sever
combin
immunodefici
scid
mice
enhanc
product
vivo
expand
spleen
cell
mice
furthermor
report
augment
antitumor
activ
presenc
absenc
base
find
suggest
abl
induc
innat
adapt
immun
respons
suppress
vivo
tumor
growth
recent
studi
bnl
hepatoma
model
also
reveal
nk
cell
implic
antitumor
activ
induc
probabl
potent
howev
contrast
detect
respons
vitro
treatment
nk
cell
suggest
may
activ
cell
mediat
nk
cell
activ
also
mark
nk
cell
infiltr
tumor
addit
lesser
extent
enhanc
immunocytotox
splenocyt
prime
irradi
bnl
cell
splenocyt
cytotox
bnl
cell
depend
mediat
dendrit
cell
contrast
nk
cell
isol
spleen
mpdca
dendrit
cell
respond
directli
suggest
effect
nk
cell
mediat
cell
dc
hand
signific
decreas
treg
observ
mice
inocul
bnl
cell
secret
wherea
moder
decreas
treg
observ
mice
receiv
bnl
cell
secret
statist
signific
therefor
antitumor
mechan
activ
may
differ
increas
number
nk
cell
tumor
site
wherea
stronger
effect
treg
bnl
model
studi
altogeth
suggest
although
signal
quit
similarli
differ
exist
biolog
potenc
kinet
set
target
cell
sensit
therefor
two
type
ifn
may
distinct
physiolog
function
unlik
small
subset
cell
sensit
impli
potenti
clinic
use
may
associ
limit
side
effect
presumpt
rais
question
whether
could
altern
cancer
therapi
howev
despit
sever
numer
side
effect
inher
treatment
believ
altern
treatment
weigh
first
real
benefit
patient
term
overal
surviv
tumor
clearanc
demonstr
bnl
hepatoma
model
combin
could
achiev
mark
antitumor
activ
comparison
use
ifn
alon
benefit
combin
therapi
demonstr
use
gene
therapi
approach
direct
administr
ifn
mice
bear
tumor
mice
inject
bnl
cell
secret
complet
reject
tumor
contrast
mice
receiv
cell
cell
furthermor
mice
bear
establish
tumor
treat
exogen
show
drastic
tumor
repress
effect
observ
ifn
deliv
local
even
low
dose
therefor
believ
simpli
act
like
reduc
side
effect
combin
achiev
effici
antitumor
activ
combin
low
dose
subtherapeut
less
toxic
may
improv
ifn
therapi
benefit
cancer
patient
combin
therapi
may
achiev
ultim
antitumor
activ
induc
complementari
mechan
directli
tumor
cell
indirectli
modul
tumor
microenviron
therebi
lead
stimul
immun
respons
tumor
inhibit
tumor
angiogenesi
act
differ
intens
target
may
gener
high
level
synergi
lead
potent
antitumor
activ
similarli
shown
play
import
role
cancer
viral
diseas
treatment
although
two
ifn
act
ident
signal
pathway
cell
pattern
activ
seem
differ
vivo
impli
redund
cytokin
act
target
differ
intens
believ
act
concert
better
control
tumor
develop
vivo
therefor
achiev
better
treatment
viral
diseas
cancer
believ
develop
combin
therapi
rather
use
ifn
alon
benefici
patient
combin
ifn
cytokin
growth
factor
antagonist
could
also
import
strategi
improv
ifn
therapi
transform
growth
factorbeta
play
dual
role
cancer
mediat
tumorsuppres
activ
earli
stage
prooncogen
activ
later
stage
tumor
progress
could
repres
one
potenti
import
modul
mediat
ifn
respons
understand
potenti
crosstalk
cytokin
growth
factor
could
reward
lead
new
preclin
studi
anim
model
new
clinic
trial
result
better
cancer
treatment
